Interfering with a series of signal pathways, including TGF-β, PI3K-Akt, Jak-STAT, MAPK, Rap1, and cell adhesion molecules, ivosidenib influenced the malignant phenotype of NSCLC cells. This evidence concerns the gene TGFB1 and non-small cell lung carcinoma.